OMass Therapeutics is a biotechnology company that develops novel medicines using native mass spectrometry and other biophysical technologies to study protein interactions.

OMass Therapeutics

MedPharma is a pharmaceutical company based in the United Kingdom that provides medication and healthcare products.

MedPharma

OMass Therapeutics is a private pharmaceutical company, focused on structural mass spectrometry to discover novel medicines. The company uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulating complex formation. These methods are being applied to drug discovery for a variety of complex targets, including membrane receptors, addressing severe unmet medical needs. OMass is backed by Syncona Ltd and Oxford Science Enterprises.

Our Director of Protein Biochemistry and Structural Biology Katharina Dürr will be presenting at the XXVIII EFMC International Symposium on Medicinal Chemistry in Rome on 4th September. 
 
Katharina’s presentation, titled ‘Cryo-EM enables Structure-Based Drug Discovery for Membrane Protein Targets’ will take place at 14:00 CET at the Palazzo dei Congressi.
 
Find out more here: https://www.efmc-ismc.org/ 
 
#drugdiscovery #masspec #biotech #lifescience #innovation #CryoEM

We are looking for a Operations Technician to join us here at 
#OMass Therapeutics in Joanne Blowers team.

This is a really exciting opportunity to be part of our growing team.

For a detailed job description and to apply directly please visit our website https://lnkd.in/ddaju6xf

#lifescience #operations #science #massspec #drugdiscovery hashtag
#development #hiring #jobs #team #laboratory #operationstechnician #technician

We are thrilled that OMass has been selected by Fierce Biotech as a “Fierce 15” honoree for 2024.

The annual Fierce 15 companies are selected for being the most innovative and promising biotechnology companies in the industry and highlights OMass as one of the most ambitious and successful next generation biopharma companies.

Ros Deegan, Chief Executive Officer at OMass Therapeutics, commented: “OMass is redefining drug discovery for previously intractable targets by fundamentally innovating the process and it is an incredible honour to be recognised by Fierce Biotech as one of the Fierce 15. Over the past year OMass made significant progress in translating the outputs of our proprietary platform into an exciting pipeline of novel drugs including advancing the development of our lead program, an insurmountable antagonist of the MC2 receptor for Congenital Adrenal Hyperplasia towards the clinic. This recognition is a testament to the dedication and hard work of our team and underlines our progress so far as well as our ambition to become a fully integrated pharma company bringing to market medicines that meaningfully improve patient lives.”

Congratulations to all of this year’s Fierce 15!

To read the full press release visit: https://lnkd.in/eZpC_r45

Read the Fierce 15 report here: https://lnkd.in/eXVdVv4z

#Fierce15 #drugdiscovery #masspec #biotech #LifeScience #innovation

Are you counting down to the #2024ParisOlympics? 
What is your #favouritebiscuit? 
 
At OMass Therapeutics we take #biscuits and #Olympics very seriously. 2024 #biscuitsolympics are in full swing! 
So far, there have been easy wins for firm favourites (Nutella biscuits, dark chocolate digestives, Pick Ups… ). Surprising heavy defeats (Hobnobs) by last minute entrants (almond & pistachio cookies). After heavy thrashing of old school favourites (Jammie dodgers, custard creams and chocolate bourbons), a few distraught loyal supporters had to be reassured that losers will not be banned from the weekly shop (phew!). 

It is no surprise that #OMassians strongly favour #chocolatecoveredbiscuits, resulting in a very #biased contestant pool going into the quarterfinals (7/8!). This makes the semis and finals … well… more or less interesting, depending on your view! Whichever way, many more biscuits will be eaten over the next few weeks until the one and only #BiscuitOlympic champion is crowned!

A huge thank you to the #CultureClub for year round efforts organising all our activities!  
Miguel Campos Silva Joanne Blowers Viviane Mignone Lauren Ross Laurence Towner Rachael Skyner Raphael Reinbold Tatiana S. Beatrice Manzan Jonathan Hopper Emma S.

Our Director of Protein Biochemistry and Structural Biology Katharina Dürr will be presenting at Gordon Research Conferences’ ‘New Insights into Structure, Function, and Regulation of Critical Membrane Transport Proteins in Health and Disease’ conference.
 
Katharina’s presentation, titled ‘From Molecules to Medicines: Advancing Small Molecule Drug Discovery for Solute Carriers with Mass Spec and Cryo-EM’ will take place at 8.40pm ET on July 24 at the Grand Summit Hotel in Newry, MA.
 
Find out more here: https://lnkd.in/eAAdfxs7
 
#drugdiscovery #masspec #biotech #LifeScience #innovation #CryoEM

We recently collaborated with Waters Corporation to develop a novel enhanced declustering device which provides sustained activation of protein ions in the first pumping stage of the mass spectrometer. This provides efficient detergent removal from membrane proteins and enables native top-down measurements of drug interactions obtained from multiplexed compound libraries.

Congratulations to our team: Kleitos Sokratous, Feng Qu, Aisha Ben-Younis, Mario Hensen, Ali Jazayeri, Idlir Liko and Jonathan Hopper.
 
Access full paper here: https://lnkd.in/ebvFGaKd

#drugdiscovery #masspec #biotech #LifeScience #innovation

OMass is a finalist for the Life Sciences & Health Tech Company of the Year at The Business Magazine - South East Thames Valley Tech and Innovation Awards 2024 tonight!
 
Good luck to all finalists!
 
#awards #drugdiscovery #masspec #biotech #LifeScience #innovation

British inventor Dame Carol Robinson claims the Lifetime Achievement award at the European #InventorAward 2024! 👏 Her 30+ year career in mass spectrometry has transformed healthcare, marking a monumental achievement. 🏆🙌 Witness this historic moment: https://lnkd.in/e2jDhNY4
 
Kavli Institute for Nanoscience Discovery, University of Oxford University of Oxford Oxford Chemistry Oxford University Innovation The Kavli Foundation OMass Therapeutics

We are thrilled to announce that our Founder and Chair of our Scientific Advisory Board, Professor Dame Carol Robinson has won the European Patent Office - Lifetime Achievement prize at the European #InventorAward 2024. 
 
Carol’s pioneering work in mass spectrometry allows for the characterisation of proteins in their native state and is a key part of OMass’ drug discovery platform, OdyssIONTM. 
 
To read more Carol’s inspiring story, go to: https://lnkd.in/dN7cMJN9 
 
#Award #Biotech #DrugDiscovery #MassSpec #LifeSciences #Innovation

Congratulations to our Founder and Chair of our Scientific Advisory Board, Professor Dame Carol Robinson for receiving an honorary doctorate from the University of Cambridge in recognition of her achievements in the field of native mass spectrometry!
 
Read more here: https://lnkd.in/dCx-mX3E 
 
#Biotech #DrugDiscovery #MassSpec #LifeSciences #Innovation

Metric
Company Name	OMass Therapeutics	MedPharma
Symbol
MSH ID	COM:OMASS	UK:MEDPHARMA
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Pharmaceuticals
Country	GB	GB
Stage
Employee Count	11
Website	omass.com	medpharma.uk
LinkedIn	omass-therapeutics	medpharm
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	1
Web Traffic Growth	-1.00
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

OMAS

COM:OMASS

OMass Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue